Research ArticleOriginal Article

Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA

Kenan Zhang, Xing Liu, Guanzhang Li, Xin Chang, Shouwei Li, Jing Chen, Zheng Zhao, Jiguang Wang, Tao Jiang and Ruichao Chai
Cancer Biology & Medicine October 2022, 19 (10) 1460-1476; DOI: https://doi.org/10.20892/j.issn.2095-3941.2022.0469

References

  1. 1.↵
    2. Ostrom QT,
    3. Cioffi G,
    4. Waite K,
    5. Kruchko C,
    6. Barnholtz-Sloan JS.
    CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 2021; 23: iii1–iii105.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Jiang T,
    3. Nam DH,
    4. Ram Z,
    5. Poon WS,
    6. Wang J,
    7. Boldbaatar D, et al.
    Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2021; 499: 60–72.
    OpenUrl
  3. 3.↵
    2. Jiang T,
    3. Tang GF,
    4. Lin Y,
    5. Peng XX,
    6. Zhang X,
    7. Zhai XW, et al.
    Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study. Chin Med J (Engl). 2011; 124: 2578–83.
    OpenUrlPubMed
  4. 4.
    2. Liu J,
    3. Li C,
    4. Wang Y,
    5. Ji P,
    6. Guo S,
    7. Zhai Y, et al.
    Prognostic and predictive factors in elderly patients with glioblastoma: a single-center retrospective study. Front Aging Neurosci. 2021; 13: 777962.
  5. 5.↵
    2. Zheng R,
    3. Zhang S,
    4. Zeng H,
    5. Wang S,
    6. Sun K,
    7. Chen R, et al.
    Cancer incidence and mortality in China, 2016. J Natl Cancer Center. 2022; 2: 1–9.
    OpenUrl
  6. 6.↵
    2. Yang P,
    3. Wang Y,
    4. Peng X,
    5. You G,
    6. Zhang W,
    7. Yan W, et al.
    Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol. 2013; 113: 259–66.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Xu YY,
    3. Gao P,
    4. Sun Y,
    5. Duan YR.
    Development of targeted therapies in treatment of glioblastoma. Cancer Biol Med. 2015; 12: 223–37.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    2. Chai RC,
    3. Liu YQ,
    4. Zhang KN,
    5. Wu F,
    6. Zhao Z,
    7. Wang KY, et al.
    A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas. Mod Pathol. 2019; 32: 4–15.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Chai R,
    3. Li G,
    4. Liu Y,
    5. Zhang K,
    6. Zhao Z,
    7. Wu F, et al.
    Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma. Cancer Biol Med. 2021; 18: 272–82.
    OpenUrl
  10. 10.↵
    2. Yan H,
    3. Parsons DW,
    4. Jin G,
    5. McLendon R,
    6. Rasheed BA,
    7. Yuan W, et al.
    IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765–73.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.
    2. Labussiere M,
    3. Idbaih A,
    4. Wang XW,
    5. Marie Y,
    6. Boisselier B,
    7. Falet C, et al.
    All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010; 74: 1886–90.
    OpenUrlCrossRefPubMed
  12. 12.↵
    2. Xie Y,
    3. Tan Y,
    4. Yang C,
    5. Zhang X,
    6. Xu C,
    7. Qiao X, et al.
    Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis. Cancer Biol Med. 2019; 16: 784–96.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    2. Louis DN,
    3. Perry A,
    4. Reifenberger G,
    5. von Deimling A,
    6. Figarella-Branger D,
    7. Cavenee WK, et al.
    The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016; 131: 803–20.
    OpenUrlCrossRefPubMed
  14. 14.↵
    2. Chai RC,
    3. Li YM,
    4. Zhang KN,
    5. Chang YZ,
    6. Liu YQ,
    7. Zhao Z, et al.
    RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. JCI Insight. 2019; 5.
  15. 15.↵
    2. Chai RC,
    3. Chang YZ,
    4. Chang X,
    5. Pang B,
    6. An SY,
    7. Zhang KN, et al.
    YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-kB and promote the malignant progression of glioma. J Hematol Oncol. 2021; 14: 109.
    OpenUrlPubMed
  16. 16.↵
    2. Ludwig K,
    3. Kornblum HI.
    Molecular markers in glioma. J Neurooncol. 2017; 134: 505–12.
    OpenUrlCrossRefPubMed
  17. 17.
    2. Wesseling P,
    3. Capper D.
    WHO 2016 Classification of gliomas. Neuropathol Appl Neurobiol. 2018; 44: 139–50.
    OpenUrlCrossRefPubMed
  18. 18.↵
    2. Chai RC,
    3. Zhang KN,
    4. Chang YZ,
    5. Wu F,
    6. Liu YQ,
    7. Zhao Z, et al.
    Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. Carcinogenesis. 2019; 40: 1229–39.
    OpenUrl
  19. 19.↵
    2. Eckel-Passow JE,
    3. Lachance DH,
    4. Molinaro AM,
    5. Walsh KM,
    6. Decker PA,
    7. Sicotte H, et al.
    Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015; 372: 2499–508.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Wahl M,
    3. Phillips JJ,
    4. Molinaro AM,
    5. Lin Y,
    6. Perry A,
    7. Haas-Kogan DA, et al.
    Chemotherapy for adult low-grade gliomas: Clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol. 2017; 19: 242–51.
    OpenUrl
  21. 21.↵
    2. Cairncross G,
    3. Wang M,
    4. Shaw E,
    5. Jenkins R,
    6. Brachman D,
    7. Buckner J, et al.
    Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013; 31: 337–43.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    2. Ding X,
    3. Wang Z,
    4. Chen D,
    5. Wang Y,
    6. Zhao Z,
    7. Sun C, et al.
    The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study. J Neurooncol. 2018; 140: 591–603.
    OpenUrl
  23. 23.↵
    2. Jakola AS,
    3. Pedersen LK,
    4. Skjulsvik AJ,
    5. Myrmel K,
    6. Sjavik K,
    7. Solheim O.
    The impact of resection in IDH-mutant WHO grade 2 gliomas: a retrospective population-based parallel cohort study. J Neurosurg. 2022; 1–8.
  24. 24.↵
    2. Hou Z,
    3. Zhang K,
    4. Liu X,
    5. Fang S,
    6. Li L,
    7. Wang Y, et al.
    Molecular subtype impacts surgical resection in low-grade gliomas: a Chinese glioma genome atlas database analysis. Cancer Lett. 2021; 522: 14–21.
    OpenUrl
  25. 25.↵
    2. Li SW,
    3. Qiu XG,
    4. Chen BS,
    5. Zhang W,
    6. Ren H,
    7. Wang ZC, et al.
    Prognostic factors influencing clinical outcomes of glioblastoma multiforme. Chin Med J (Engl). 2009; 122: 1245–9.
    OpenUrlPubMed
  26. 26.↵
    2. Zhao Z,
    3. Zhang KN,
    4. Wang Q,
    5. Li G,
    6. Zeng F,
    7. Zhang Y, et al.
    Chinese Glioma Genome Atlas (CGGA): a comprehensive resource with functional genomic data from chinese glioma patients. Genom Proteom Bioinform. 2021; 19: 1–12.
    OpenUrl
  27. 27.↵
    2. Chai RC,
    3. Zhang KN,
    4. Liu YQ,
    5. Wu F,
    6. Zhao Z,
    7. Wang KY, et al.
    Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. CNS Neurosci Ther. 2019; 25: 314–22.
    OpenUrl
  28. 28.↵
    2. Orringer D,
    3. Lau D,
    4. Khatri S,
    5. Zamora-Berridi GJ,
    6. Zhang K,
    7. Wu C, et al.
    Extent of resection in patients with glioblastoma: Limiting factors, perception of resectability, and effect on survival. J Neurosurg. 2012; 117: 851–9.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    2. Weller M,
    3. van den Bent M,
    4. Preusser M,
    5. Le Rhun E,
    6. Tonn JC,
    7. Minniti G, et al.
    EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021; 18: 170–86.
    OpenUrlCrossRefPubMed
  30. 30.↵
    2. Mijderwijk HJ,
    3. Nieboer D,
    4. Incekara F,
    5. Berger K,
    6. Steyerberg EW,
    7. van den Bent MJ, et al.
    Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma. J Neurosurg. 2022; 1–10.
  31. 31.↵
    2. Nabors LB,
    3. Portnow J,
    4. Ahluwalia M,
    5. Baehring J,
    6. Brem H,
    7. Brem S, et al.
    Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020; 18: 1537–70.
    OpenUrlCrossRef
  32. 32.↵
    2. Lapointe S,
    3. Perry A,
    4. Butowski NA.
    Primary brain tumours in adults. Lancet. 2018; 392: 432–46.
    OpenUrlCrossRefPubMed
  33. 33.↵
    2. Rossi M,
    3. Gay L,
    4. Ambrogi F,
    5. Conti Nibali M,
    6. Sciortino T,
    7. Puglisi G, et al.
    Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. Neuro Oncol. 2021; 23: 812–26.
    OpenUrl
  34. 34.↵
    2. Mair MJ,
    3. Geurts M,
    4. van den Bent MJ,
    5. Berghoff AS.
    A basic review on systemic treatment options in WHO grade II-III gliomas. Cancer Treat Rev. 2021; 92: 102124.
  35. 35.↵
    2. Tan AC,
    3. Ashley DM,
    4. Lopez GY,
    5. Malinzak M,
    6. Friedman HS,
    7. Khasraw M.
    Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020; 70: 299–312.
    OpenUrlPubMed
  36. 36.↵
    2. Stoyanov GS,
    3. Lyutfi E,
    4. Georgieva R,
    5. Georgiev R,
    6. Dzhenkov DL,
    7. Petkova L, et al.
    Reclassification of glioblastoma multiforme according to the 2021 World Health Organization classification of central nervous system tumors: a single institution report and practical significance. Cureus. 2022; 14: e21822.
  37. 37.
    2. Mizoguchi M,
    3. Hata N,
    4. Kuga D,
    5. Hatae R,
    6. Akagi Y,
    7. Sangatsuda Y, et al.
    Clinical implications of molecular analysis in diffuse glioma stratification. Brain Tumor Pathol. 2021; 38: 210–7.
    OpenUrl
  38. 38.
    2. Ostrom QT,
    3. Shoaf ML,
    4. Cioffi G,
    5. Waite K,
    6. Kruchko C,
    7. Wen PY, et al.
    National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Neuro Oncol. 2022; noac198.
  39. 39.↵
    2. Brown NF,
    3. Ottaviani D,
    4. Tazare J,
    5. Gregson J,
    6. Kitchen N,
    7. Brandner S, et al.
    Survival outcomes and prognostic factors in glioblastoma. Cancers (Basel). 2022; 14: 3161.
    OpenUrl
  40. 40.↵
    2. Hervey-Jumper SL,
    3. Berger MS.
    Maximizing safe resection of low- and high-grade glioma. J Neurooncol. 2016; 130: 269–82.
    OpenUrlCrossRefPubMed
  41. 41.↵
    2. Karschnia P,
    3. Vogelbaum MA,
    4. van den Bent M,
    5. Cahill DP,
    6. Bello L,
    7. Narita Y, et al.
    Evidence-based recommendations on categories for extent of resection in diffuse glioma. Eur J Cancer. 2021; 149: 23–33.
    OpenUrlCrossRef
  42. 42.↵
    2. Albuquerque LAF,
    3. Almeida JP,
    4. de Macedo Filho LJM,
    5. Joaquim AF,
    6. Duffau H.
    Extent of resection in diffuse low-grade gliomas and the role of tumor molecular signature – a systematic review of the literature. Neurosurg Rev. 2021; 44: 1371–89.
    OpenUrl
  43. 43.↵
    2. Still MEH,
    3. Roux A,
    4. Huberfeld G,
    5. Bauchet L,
    6. Baron MH,
    7. Fontaine D, et al.
    Extent of resection and residual tumor thresholds for postoperative total seizure freedom in epileptic adult patients harboring a supratentorial diffuse low-grade glioma. Neurosurgery. 2019; 85: E332–40.
    OpenUrl
  44. 44.↵
    2. Robe PA,
    3. Rados M,
    4. Spliet WG,
    5. Hoff RG,
    6. Gosselaar P,
    7. Broekman MLD, et al.
    Early surgery prolongs professional activity in IDH mutant low-grade glioma patients: a policy change analysis. Front Oncol. 2022; 12: 851803.
  45. 45.↵
    2. Mladenovsk M,
    3. Valkov I,
    4. Ovcharov M,
    5. Vasilev N,
    6. Duhlenski I.
    High grade glioma surgery – clinical aspects and prognosis. Folia Med (Plovdiv). 2021; 63: 35–41.
    OpenUrl
  46. 46.↵
    2. Hollon T,
    3. Hervey-Jumper SL,
    4. Sagher O,
    5. Orringer DA.
    Advances in the surgical management of low-grade glioma. Semin Radiat Oncol. 2015; 25: 181–8.
    OpenUrl
  47. 47.↵
    2. Mirza FA,
    3. Shamim MS.
    Extent of resection and timing of surgery in adult low grade glioma. J Pak Med Assoc. 2017; 67: 959–61.
    OpenUrl
  48. 48.↵
    2. Gutman DC,
    3. Young RJ.
    IDH glioma radiogenomics in the era of deep learning. Neuro Oncol. 2021; 23: 182–3.
    OpenUrl
  49. 49.
    2. Singh G,
    3. Manjila S,
    4. Sakla N,
    5. True A,
    6. Wardeh AH,
    7. Beig N, et al.
    Radiomics and radiogenomics in gliomas: a contemporary update. Br J Cancer. 2021; 125: 641–57.
    OpenUrl
  50. 50.↵
    2. Kazerooni AF,
    3. Bakas S,
    4. Rad HS,
    5. Davatzikos C.
    Imaging signatures of glioblastoma molecular characteristics: a radiogenomics review. J Magn Reson Imaging. 2020; 52: 54–69.
    OpenUrl
  51. 51.↵
    2. Li Y,
    3. Qian Z,
    4. Xu K,
    5. Wang K,
    6. Fan X,
    7. Li S, et al.
    MRI features predict p53 status in lower-grade gliomas via a machine-learning approach. Neuroimage Clin. 2018; 17: 306–11.
    OpenUrl
  52. 52.
    2. Fang S,
    3. Liang Y,
    4. Li L,
    5. Wang L,
    6. Fan X,
    7. Wang Y, et al.
    Tumor location-based classification of surgery-related language impairments in patients with glioma. J Neurooncol. 2021; 155: 143–52.
    OpenUrl
  53. 53.↵
    2. Liu X,
    3. Li Y,
    4. Li S,
    5. Fan X,
    6. Sun Z,
    7. Yang Z, et al.
    IDH mutation-specific radiomic signature in lower-grade gliomas. Aging (Albany NY). 2019; 11: 673–96.
    OpenUrl
  54. 54.↵
    2. Yu Y,
    3. Villanueva-Meyer J,
    4. Grimmer MR,
    5. Hilz S,
    6. Solomon DA,
    7. Choi S, et al.
    Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol. 2021; 23: 1872–84.
    OpenUrl
  55. 55.↵
    2. Gramatzki D,
    3. Felsberg J,
    4. Roth P,
    5. Kaulich K,
    6. von Deimling A,
    7. Rushing EJ, et al.
    The molecular evolution of glioblastoma treated by gross total resection alone. Neuro Oncol. 2021; 23: 334–6.
    OpenUrl
  56. 56.↵
    2. Tavelin B,
    3. Malmstrom A.
    Sex differences in glioblastoma-findings from the swedish national quality registry for primary brain tumors between 1999-2018. J Clin Med. 2022; 11: 486.
    OpenUrl
  57. 57.
    2. Moore KJ,
    3. Moertel CL,
    4. Williams LA.
    Young adult males have worse survival than females that is largely independent of treatment received for many types of central nervous system tumors: a National Cancer Database Analysis. Cancer. 2022; 128: 1616–25.
    OpenUrl
  58. 58.
    2. Wang GM,
    3. Cioffi G,
    4. Patil N,
    5. Waite KA,
    6. Lanese R,
    7. Ostrom QT, et al.
    Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. Neuro Oncol. 2022; 24: 302–10.
    OpenUrl
  59. 59.↵
    2. Alexopoulos G,
    3. Zhang J,
    4. Karampelas I,
    5. Patel M,
    6. Kemp J,
    7. Coppens J, et al.
    Long-term time series forecasting and updates on survival analysis of glioblastoma multiforme: a 1975-2018 population-based study. Neuroepidemiology. 2022; 56: 75–89.
    OpenUrl
  60. 60.↵
    2. Hirtz A,
    3. Rech F,
    4. Dubois-Pot-Schneider H,
    5. Dumond H.
    Astrocytoma: a hormone-sensitive tumor? Int J Mol Sci. 2020; 21: 9114.
    OpenUrl
  61. 61.↵
    2. Eldesouki S,
    3. Samara KA,
    4. Qadri R,
    5. Obaideen AA,
    6. Otour AH,
    7. Habbal O, et al.
    XIST in brain cancer. Clin Chim Acta. 2022; 531: 283–90.
    OpenUrl
  62. 62.↵
    2. Louis DN,
    3. Wesseling P,
    4. Paulus W,
    5. Giannini C,
    6. Batchelor TT,
    7. Cairncross JG, et al.
    cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathol. 2018; 135: 481–4.
    OpenUrlCrossRefPubMed
  63. 63.↵
    2. Louis DN,
    3. Perry A,
    4. Wesseling P,
    5. Brat DJ,
    6. Cree IA,
    7. Figarella-Branger D, et al.
    The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021; 23: 1231–51.
    OpenUrlCrossRefPubMed
  64. 64.↵
    2. Huang LE.
    Impact of CDKN2A/B homozygous deletion on the prognosis and biology of IDH-mutant glioma. Biomedicines. 2022; 10: 246.
    OpenUrl
  65. 65.↵
    2. Aoki K,
    3. Nakamura H,
    4. Suzuki H,
    5. Matsuo K,
    6. Kataoka K,
    7. Shimamura T, et al.
    Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 2018; 20: 66–77.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords